CAMP.US CAMP4 THERAPEUTICS CORPORATION

Healthcare Biotechnology USA Stocks
3.80 USD
Close of Nov 14, 2026
2.90 7.75
Market cap
USD 238M
P/E
-
P/B
2.40x
ROE
-100.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CAMP.US undervalued?

Graham number

The Graham number of CAMP4 THERAPEUTICS CORPORATION cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CAMP4 THERAPEUTICS CORPORATION fundamental analysis

No fundamental analysis for CAMP4 THERAPEUTICS CORPORATION yet.

CAMP4 THERAPEUTICS CORPORATION stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CAMP4 THERAPEUTICS CORPORATION

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Thera…

Full company profile